References
- Abbas H, Elyamany A, Salem M, et al (2011). The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med, 4, 35. https://doi.org/10.1186/1755-7682-4-35
- Arends L, Hunink M, Stijnen T, et al (2008). Meta-analysis of summary survival curve data. Stat Med, 27, 4381-96. https://doi.org/10.1002/sim.3311
- Arkoob K, Al-Nsour M, Al-Nemry O, et al (2010). Epidemiology of breast cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Health J, 16, 1032-8.
- Azrif M, Ibrahim J, Aslan N, et al (2011). Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital. Asian Pac J Cancer Prev, 12, 157-62.
- Camlibel B, Dine S (2005). A comparison of the outcomes of non-randomized chemotherapy regimens in node positive breast cancer. J Exp Clin Cancer, 24, 363-72.
- Chen D, Lai L, Duan C, et al (2014). Conservative surgery plus axillary radiotherapy vs modified radical mastectomy in patients with stage I breast cancer. Clin Breast Cancer, 14, 10-3. https://doi.org/10.1016/j.clbc.2013.08.010
- Chen S, Huang L, Liu Y, et al (2013). The predictive and prognostic significance of pre- and post-treatment topoisomerase IIalpha in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer. Eur J Surg Oncol, 39, 619-26. https://doi.org/10.1016/j.ejso.2013.02.019
- Dear KB (1994). Iterative generalized least squares for metaanalysis of survival data at multiple times. Biometrics, 989-1002.
- DerSimonian R, Kacker R (2007). Random-effects model for meta-analysis of clinical trials: an update. Contemporary Clinical Trials, 28, 105-14. https://doi.org/10.1016/j.cct.2006.04.004
- Duman B, Afsar C, Gunaldi M, et al (2012). Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients. Asian Pac J Cancer Prev, 13, 4119-23. https://doi.org/10.7314/APJCP.2012.13.8.4119
- Earl H, Hiller M, Dunn J, et al (2012). Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. Br J Cancer, 107, 1257-67. https://doi.org/10.1038/bjc.2012.370
- Faradmal J, Kazemnejad A, Bakhshi R (2010). Comparing three adjuvant chemotherapy regimes after modified radical mastectomy in breast cancer patients using log-logistic model. J Semnan Univ Med Sci, 11, 279-86.
- Gogia A, Raina V, Deo S, et al (2014). Inflammatory breast cancer: a single centre analysis. Asian Pac J Cancer Prev, 15, 3207-10. https://doi.org/10.7314/APJCP.2014.15.7.3207
- Gupta D, Raina V, Rath G, et al (2011). Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer and comparison with anthracycline-based chemotherapies: eight-year experience from single centre. Indian J Cancer, 48, 410-4. https://doi.org/10.4103/0019-509X.92258
- Guyot P, Ades A, Ouwens M, et al (2012). Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol, 12, 9. https://doi.org/10.1186/1471-2288-12-9
- Ismaili N, Elmajjaoui S, Lalya I, et al (2010). Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution. BMC Res Notes, 3, 247.
- Ismaili N, Mellas N, Masbah O, et al (2009). Concurrent chemoradiotherapy in adjuvant treatment of breast cancer. Radiat Oncol, 4, 12. https://doi.org/10.1186/1748-717X-4-12
- Ji M, Tang J, Zhao J (2012). Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracyclinebased neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biology Therapy, 13, 264-71. https://doi.org/10.4161/cbt.18920
- Katalinic A, Pritzkuleit R , Waldmann A (2009). Recent trends in breast cancer incidence and mortality in Germany. Breast Care (Basel), 4, 75-80. https://doi.org/10.1159/000211526
- Klein M (2005). Survival analysis: a self-learning text, Springer.
- Leo A, Desmedt C, Bartlett J, et al (2011). HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol, 12, 1134-42. https://doi.org/10.1016/S1470-2045(11)70231-5
- Li L, Xu X, Zhao Y, et al (2009). Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res Treat, 113, 231-7. https://doi.org/10.1007/s10549-008-9925-4
- Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91. https://doi.org/10.1111/j.1524-4741.2007.00446.x
- Phua C, Bustam A, Yusof M, et al (2012). Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. Asian Pac J Cancer Prev, 13, 4623-6. https://doi.org/10.7314/APJCP.2012.13.9.4623
- Sharif F, Abshorshori N, Tahmasebi S, et al (2010). The effect of peer-led education on the life quality of mastectomy patients referred to breast cancer-clinics in Shiraz, Iran 2009. Health Qual Life Outcomes, 8, 74. https://doi.org/10.1186/1477-7525-8-74
- Sharma B, Satyanarayan A, Kalwar N, et al (2013). Five year retrospective survival analysis of triple negative breast cancer in North-West India. Indian J Cancer, 50, 330-2. https://doi.org/10.4103/0019-509X.123616
- Society AC (2007). Breast cancer facts & figures 2007-2008, American cancer society Atlanta.
- Tokiniwa H, Horiguchi J, Takata D, et al (2012). Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer, 19, 309-14. https://doi.org/10.1007/s12282-011-0291-4
- Wakamatsu S, Mitsuyama S, Nanba K, et al (2006). Adjuvant therapy for breast cancer in Kyushu. Breast Cancer, 13, 308-12. https://doi.org/10.2325/jbcs.13.308
- Wang S, Shi Y, Yuan Z, et al (2012). Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxanebased regimens. Medical Oncol, 29, 547-53. https://doi.org/10.1007/s12032-011-9964-2
- Wu H, Kang H, Liu Y, et al (2012). Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J Cancer Res Clin Oncol, 138, 1449-62. https://doi.org/10.1007/s00432-012-1209-z
- Xue C, Wang X, Peng R, et al (2012). Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci, 103, 1679-87. https://doi.org/10.1111/j.1349-7006.2012.02339.x
- Yao L, Liu Y, Li Z, et al (2011). HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Ann Oncol, 22, 1326-31. https://doi.org/10.1093/annonc/mdq612
- Zare N, Doostfatemeh M, Rezaianzadeh A (2012). Modeling of breast cancer prognostic factors using a parametric loglogistic model in Fars province, Southern Iran. Asian Pac J Cancer Prev, 13, 1533-7. https://doi.org/10.7314/APJCP.2012.13.4.1533
- Zare N, Ghanbari S, Salehi A (2013). Effects of two chemotherapy regimens, anthracycline-based and CMF, on breast cancer disease free survival in the Eastern Mediterranean Region and Asia: a meta-analysis approach for survival curves. Asian Pac J Cancer Prev, 14, 2013-7. https://doi.org/10.7314/APJCP.2013.14.3.2013
- Zare N, Haem E, Lankarani KB, et al (2013). Breast cancer risk factors in a defined population: weighted logistic regression approach for rare events. J Breast Cancer, 16, 214-9. https://doi.org/10.4048/jbc.2013.16.2.214
- Zhang J, Liu Y (2008). HER2 over-expression and response to different chemotherapy regimens in breast cancer. J Zhejiang Univ Sci B, 9, 5-9. https://doi.org/10.1631/jzus.B073003
Cited by
- Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients vol.79, pp.3, 2017, https://doi.org/10.1007/s00280-017-3248-2